DMACDiaMedica Therapeutics Inc
$7.32
$0.3242
(4.24%)
Pre-Market
EarningsAug 11
Mkt Cap$400.35M
Vol7.00
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199...
Business Wire
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, today announced that it has received a written response from the U.S. Food and Drug Administration (FDA) regarding the need for additional nonclinical reproductive toxicity data to support continued development...
Business Wire
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the Company will present at the 2026 Jefferies Global Healthcare Conference being held...
Business Wire
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke, preeclampsia and fetal growth restriction, today announced that enrollment in its pivotal Phase 2/3 ReMEDy2 trial of DM199 (rinvecalinase alfa) in...
Business Wire
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...
Business Wire
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia (PE), fetal growth restriction (FGR) and acute ischemic...
Business Wire
DiaMedica Therapeutics (DMAC) Expected to Announce Quarterly Earnings on Wednesday
DiaMedica Therapeutics (NASDAQ:DMAC) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-diamedica-therapeutics-inc-stock...
MarketBeat
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke...
Business Wire
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives Average Rating of "Moderate Buy" from Brokerages
DiaMedica Therapeutics, Inc. (NASDAQ:DMAC - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are covering the company, MarketBeat.com reports. One...
MarketBeat
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
DiaMedica Therapeutics (NASDAQ:DMAC) President and CEO Rick Pauls outlined the company's development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor...
MarketBeat
<
1
2
...
>
Advertisement|Remove ads.
Latest DMAC News
ViewDiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
Business Wire
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
Business Wire
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
Business Wire
Advertisement|Remove ads.